Insider · CIK 0001796356
Column Group IV GP, LP
Files at EIKN (Eikon Therapeutics, Inc.). First filing Feb 9, 2026, latest Sep 8, 2026.
Column Group IV GP, LP files SEC Form 4 as 10% owner at EIKN (Eikon Therapeutics, Inc.). Since Feb 9, 2026, Column Group IV GP, LP has reported 2 open-market buys worth $39M and 0 open-market sells worth $0, the latest filed on Sep 8, 2026.
A track record needs three past buys with six months of prices behind them; Column Group IV GP, LP has 0, so none is measured yet.
The newest scored trade: bought $1.0M of EIKN on Sep 3, 2026, filed Sep 8, 2026, scored 40 (moderate). In the last 12 months: 2 buys worth $39M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EIKN: Eikon Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | EIKNbuy Eikon Therapeutics, Inc. | $1.0M 89,200 shares | - | - | |
| 67Notable | Eikon Therapeutics, Inc. | $38M 2,117,760 shares | +74% | 0% from low-3% from high |
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | EIKN Eikon Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnote | +89,200 | $11.56 | $1.0M | 89,200 | 35 d ago |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: By The Column Group IV, LP | +1,296,629 | - | - | 1,360,320 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: By The Column Group IV, LP | +1,403,568 | - | - | 2,763,888 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: By The Column Group IV, LP | +110,928 | - | - | 2,874,816 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: By The Column Group IV-A, LP | +44,249 | - | - | 47,601 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: By The Column Group IV-A, LP | +47,898 | - | - | 95,499 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: By The Column Group IV-A, LP | +3,785 | - | - | 99,284 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: By The Column Group Opportunity III, LP | +688,283 | - | - | 688,283 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | POpen-market purchase Common Stockindirect: By The Column Group IV, LP | +1,437,323 | $18.00 | $26M | 4,312,139 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | POpen-market purchase Common Stockindirect: By The Column Group IV-A, LP | +49,556 | $18.00 | $892k | 148,840 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | POpen-market purchase Common Stockindirect: By The Column Group Opportunity III, LP | +630,881 | $18.00 | $11M | 1,319,164 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series A Preferred Stockderivativeindirect: By The Column Group IV, LP | -9,670,000 | - | - | 0 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series A Preferred Stockderivativeindirect: By The Column Group IV-A, LP | -330,000 | - | - | 0 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series A-1 Preferred Stockderivativeindirect: By The Column Group IV, LP | -10,467,526 | - | - | 0 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series A-1 Preferred Stockderivativeindirect: By The Column Group IV-A, LP | -357,216 | - | - | 0 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series C-1 Preferred Stockderivativeindirect: By The Column Group IV, LP | -827,278 | - | - | 0 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series C-1 Preferred Stockderivativeindirect: By The Column Group IV-A, LP | -28,229 | - | - | 0 | Feb 9, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series D Preferred Stockderivativeindirect: By The Column Group Opportunity III, LP | -5,133,076 | - | - | 0 | Feb 9, 2026 |
Questions about Column Group IV GP, LP
Answered from the filings on this page, as of the latest one.
Is Column Group IV GP, LP buying or selling?
In the last 12 months Column Group IV GP, LP reported 2 open-market buys worth $39M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $1.0M of EIKN on Sep 3, 2026. Grants, option exercises and tax withholding are not counted.
How did Column Group IV GP, LP's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Column Group IV GP, LP has 0.
Where does Column Group IV GP, LP file Form 4?
Column Group IV GP, LP has filed Form 4 at EIKN (Eikon Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.